CARCINOMA SÓLIDO DE GLÂNDULA MAMÁRIA COM METÁSTASE EM MEDULA ESPINHAL

Neoplasias mamárias são comuns entre as fê­meas caninas e os carcinomas, dentre as formas malignas, ocorrem com maior frequência, particularmente o tipo sólido. Estes podem apresentar-se pequenos e incipientes à macroscopia, contudo são invasivos e pouco diferenciados, com possibilidade de produzir metástases que comprometem a sobrevida do animal. Assim, descreve-se o caso de uma cadela, da raça Fila Brasileiro, de seis anos, que apresentou tetraplegia consequente à metástase medular cervical de carcinoma sólido mamário. PALAVRAS-CHAVES: Cão, neoplasia mamária, sistema nervoso central

Rationale, study design, and analysis plan of the Alveolar Recruitment for ARDS Trial (ART): Study protocol for a randomized controlled trial

Background: Acute respiratory distress syndrome (ARDS) is associated with high in-hospital mortality. Alveolar recruitment followed by ventilation at optimal titrated PEEP may reduce ventilator-induced lung injury and improve oxygenation in patients with ARDS, but the effects on mortality and other clinical outcomes remain unknown. This article reports the rationale, study design, and analysis plan of the Alveolar Recruitment for ARDS Trial (ART). Methods/Design: ART is a pragmatic, multicenter, randomized (concealed), controlled trial, which aims to determine if maximum stepwise alveolar recruitment associated with PEEP titration is able to increase 28-day survival in patients with ARDS compared to conventional treatment (ARDSNet strategy). We will enroll adult patients with ARDS of less than 72 h duration. The intervention group will receive an alveolar recruitment maneuver, with stepwise increases of PEEP achieving 45 cmH(2)O and peak pressure of 60 cmH2O, followed by ventilation with optimal PEEP titrated according to the static compliance of the respiratory system. In the control group, mechanical ventilation will follow a conventional protocol (ARDSNet). In both groups, we will use controlled volume mode with low tidal volumes (4 to 6 mL/kg of predicted body weight) and targeting plateau pressure <= 30 cmH2O. The primary outcome is 28-day survival, and the secondary outcomes are: length of ICU stay; length of hospital stay; pneumothorax requiring chest tube during first 7 days; barotrauma during first 7 days; mechanical ventilation-free days from days 1 to 28; ICU, in-hospital, and 6-month survival. ART is an event-guided trial planned to last until 520 events (deaths within 28 days) are observed. These events allow detection of a hazard ratio of 0.75, with 90% power and two-tailed type I error of 5%. All analysis will follow the intention-to-treat principle. Discussion: If the ART strategy with maximum recruitment and PEEP titration improves 28-day survival, this will represent a notable advance to the care of ARDS patients. Conversely, if the ART strategy is similar or inferior to the current evidence-based strategy (ARDSNet), this should also change current practice as many institutions routinely employ recruitment maneuvers and set PEEP levels according to some titration method.Hospital do Coracao (HCor) as part of the Program 'Hospitais de Excelencia a Servico do SUS (PROADI-SUS)'Brazilian Ministry of Healt

Adding 6 months of androgen deprivation therapy to postoperative radiotherapy for prostate cancer: a comparison of short-course versus no androgen deprivation therapy in the RADICALS-HD randomised controlled trial

Background Previous evidence indicates that adjuvant, short-course androgen deprivation therapy (ADT) improves metastasis-free survival when given with primary radiotherapy for intermediate-risk and high-risk localised prostate cancer. However, the value of ADT with postoperative radiotherapy after radical prostatectomy is unclear. Methods RADICALS-HD was an international randomised controlled trial to test the efficacy of ADT used in combination with postoperative radiotherapy for prostate cancer. Key eligibility criteria were indication for radiotherapy after radical prostatectomy for prostate cancer, prostate-specific antigen less than 5 ng/mL, absence of metastatic disease, and written consent. Participants were randomly assigned (1:1) to radiotherapy alone (no ADT) or radiotherapy with 6 months of ADT (short-course ADT), using monthly subcutaneous gonadotropin-releasing hormone analogue injections, daily oral bicalutamide monotherapy 150 mg, or monthly subcutaneous degarelix. Randomisation was done centrally through minimisation with a random element, stratified by Gleason score, positive margins, radiotherapy timing, planned radiotherapy schedule, and planned type of ADT, in a computerised system. The allocated treatment was not masked. The primary outcome measure was metastasis-free survival, defined as distant metastasis arising from prostate cancer or death from any cause. Standard survival analysis methods were used, accounting for randomisation stratification factors. The trial had 80% power with two-sided α of 5% to detect an absolute increase in 10-year metastasis-free survival from 80% to 86% (hazard ratio [HR] 0·67). Analyses followed the intention-to-treat principle. The trial is registered with the ISRCTN registry, ISRCTN40814031, and ClinicalTrials.gov, NCT00541047. Findings Between Nov 22, 2007, and June 29, 2015, 1480 patients (median age 66 years [IQR 61–69]) were randomly assigned to receive no ADT (n=737) or short-course ADT (n=743) in addition to postoperative radiotherapy at 121 centres in Canada, Denmark, Ireland, and the UK. With a median follow-up of 9·0 years (IQR 7·1–10·1), metastasis-free survival events were reported for 268 participants (142 in the no ADT group and 126 in the short-course ADT group; HR 0·886 [95% CI 0·688–1·140], p=0·35). 10-year metastasis-free survival was 79·2% (95% CI 75·4–82·5) in the no ADT group and 80·4% (76·6–83·6) in the short-course ADT group. Toxicity of grade 3 or higher was reported for 121 (17%) of 737 participants in the no ADT group and 100 (14%) of 743 in the short-course ADT group (p=0·15), with no treatment-related deaths. Interpretation Metastatic disease is uncommon following postoperative bed radiotherapy after radical prostatectomy. Adding 6 months of ADT to this radiotherapy did not improve metastasis-free survival compared with no ADT. These findings do not support the use of short-course ADT with postoperative radiotherapy in this patient population

Duration of androgen deprivation therapy with postoperative radiotherapy for prostate cancer: a comparison of long-course versus short-course androgen deprivation therapy in the RADICALS-HD randomised trial

Background Previous evidence supports androgen deprivation therapy (ADT) with primary radiotherapy as initial treatment for intermediate-risk and high-risk localised prostate cancer. However, the use and optimal duration of ADT with postoperative radiotherapy after radical prostatectomy remains uncertain. Methods RADICALS-HD was a randomised controlled trial of ADT duration within the RADICALS protocol. Here, we report on the comparison of short-course versus long-course ADT. Key eligibility criteria were indication for radiotherapy after previous radical prostatectomy for prostate cancer, prostate-specific antigen less than 5 ng/mL, absence of metastatic disease, and written consent. Participants were randomly assigned (1:1) to add 6 months of ADT (short-course ADT) or 24 months of ADT (long-course ADT) to radiotherapy, using subcutaneous gonadotrophin-releasing hormone analogue (monthly in the short-course ADT group and 3-monthly in the long-course ADT group), daily oral bicalutamide monotherapy 150 mg, or monthly subcutaneous degarelix. Randomisation was done centrally through minimisation with a random element, stratified by Gleason score, positive margins, radiotherapy timing, planned radiotherapy schedule, and planned type of ADT, in a computerised system. The allocated treatment was not masked. The primary outcome measure was metastasis-free survival, defined as metastasis arising from prostate cancer or death from any cause. The comparison had more than 80% power with two-sided α of 5% to detect an absolute increase in 10-year metastasis-free survival from 75% to 81% (hazard ratio [HR] 0·72). Standard time-to-event analyses were used. Analyses followed intention-to-treat principle. The trial is registered with the ISRCTN registry, ISRCTN40814031, and ClinicalTrials.gov , NCT00541047 . Findings Between Jan 30, 2008, and July 7, 2015, 1523 patients (median age 65 years, IQR 60–69) were randomly assigned to receive short-course ADT (n=761) or long-course ADT (n=762) in addition to postoperative radiotherapy at 138 centres in Canada, Denmark, Ireland, and the UK. With a median follow-up of 8·9 years (7·0–10·0), 313 metastasis-free survival events were reported overall (174 in the short-course ADT group and 139 in the long-course ADT group; HR 0·773 [95% CI 0·612–0·975]; p=0·029). 10-year metastasis-free survival was 71·9% (95% CI 67·6–75·7) in the short-course ADT group and 78·1% (74·2–81·5) in the long-course ADT group. Toxicity of grade 3 or higher was reported for 105 (14%) of 753 participants in the short-course ADT group and 142 (19%) of 757 participants in the long-course ADT group (p=0·025), with no treatment-related deaths. Interpretation Compared with adding 6 months of ADT, adding 24 months of ADT improved metastasis-free survival in people receiving postoperative radiotherapy. For individuals who can accept the additional duration of adverse effects, long-course ADT should be offered with postoperative radiotherapy. Funding Cancer Research UK, UK Research and Innovation (formerly Medical Research Council), and Canadian Cancer Society

Expression of tansforming growth factor B and tissue inhibitor of metalloproteianse 1 and 2 in normal canine prostates and with proliferative lessions

Made available in DSpace on 2014-07-29T15:07:41Z (GMT). No. of bitstreams: 1 Dissertacao_Denise C Toledo.pdf: 1395118 bytes, checksum: 592dff1a4d2ff80089be7e8691c93893 (MD5) Previous issue date: 2012-03-08The canine gland has drawn interest for research due to its similarities with the human prostate and the great incidence of lesions. Moreover, the canine prostate shows high incidence of diseases. The main lesions that affect the prostate are prostatitis, benign prostatic hyperplasia (BPH), cysts and adenocarcinoma. Recently attention has been given to lesions considered premalignant such as prostatic intraepithelial neoplasia (PIN) and proliferative inflammatory atrophy (PIA), both studied in the human gland and also found in the canine prostate. In order to evaluate the development of prostate cancer starting as premalignant lesions, some immunohistochemical markers are employed, such as tissue inhibitors of metalloproteinases (TIMP), which have a key role in regulating the catalytic action of metalloproteinases (MMP), and transforming growth factor-β (TGF-β), that induces angiogenesis and inhibits cell proliferation and is considered a mediator of prostate growth. The objective of this study was to investigate the expression of TIMP-1, TIMP-2 and TGF-β in canine normal prostate tissue and with proliferative lesions. For this, 150 adult canine prostates were obtained from postmortem examinations. After microscopic evaluation 54 glands, compatible with normal, epithelial BPH, stromal BPH, PIA, PIN and adenocarcinoma were selected and used to make tissue microarray block (Tissue Microarray - TMA). TMA slides were subjected to immunohistochemistry with anti-TIMP-1, anti-TIMP-2 and anti-TGF-β, to assess staining intensity of epithelial cells and stromal cells.Cytoplasmatic staining of canine prostate cells by TIMP-1, TIMP-2 and TGF-β was observed, with TIMP-1 and TIMP-2 being more expressed in premalignant and malignant lesions, while TGF-β was expressed mainly by normal tissue and BPH. Furthermore, there were differences in the expression between epithelial and stromal cells.A próstata canina, além das similaridades com a próstata humana, apresenta grande incidência de afecções. As principais lesões que acometem a próstata são as prostatites, a hiperplasia prostática benigna (HPB), os cistos e o adenocarcinoma, sendo que, recentemente, se tem dado atenção às lesões consideradas pré-malignas, como a neoplasia intraepitelial prostática (PIN) e a atrofia inflamatória proliferativa (PIA), ambas estudadas na glândula humana, e também verificadas na próstata do cão. Para avaliar o desenvolvimento de neoplasias prostáticas a partir das lesões pré-malignas, alguns marcadores imunoistoquímicos são empregados, como os inibidores teciduais de metaloproteinases (TIMP), que apresentam importante função na regulação da ação catalítica das metaloproteinases (MMP), e o fator de crescimento transformador β (TGF-β), que induz a angiogênese e inibe a proliferação celular, sendo considerado um mediador do crescimento prostático. O objetivo deste estudo foi verificar a expressão de TIMP-1, TIMP-2 e TGF-β no tecido prostático canino normal e com lesões proliferativas. Para isso foram colhidas, em exames necroscópicos, 150 próstatas de cães adultos e idosos. O material foi avaliado histologicamente e selecionadas amostras de 54 próstatas com predominância de histomorfologia normal, HPB epitelial, HPB estromal, PIA, PIN e adenocarcinoma, que foram utilizadas para a confecção de um bloco de microarranjo tecidual (Tissue Microarray - TMA). As lâminas de TMA foram submetidas à imunoistoquímica com os anticorpos anti-TIMP-1, anti-TIMP-2 e anti-TGF-β, sendo avaliada a intensidade de marcação das células epiteliais e estromais. Verificou-se que há marcação citoplasmática das células prostáticas caninas para TIMP-1, TIMP-2 e TGF-β, sendo as proteínas TIMP-1 e TIMP-2 mais expressas nas lesões proliferativas pré-malignas e malignas, enquanto TGF-β foi expresso principalmente pelo tecido normal e com HPB epitelial e estromal. Ainda, houve diferença de marcação entre células epiteliais e estromais

MAMMARY SOLID CARCINOMA WITH SPINAL CORD METASTASIS CARCINOMA SÓLIDO DE GLÂNDULA MAMÁRIA COM METÁSTASE EM MEDULA ESPINHAL

<div>Mammary neoplasias are common in canine females and carcinomas, among malignant types, occur frequently, especially solid form. At gross view, it can be small and incipient, but it’s invasive and show little differentiation, being able to produce metastasis that can compromise animal survive. This describes a bitch, Fila Brasileiro, six year old with tetraplegy and cervical spinal cord metastasis of mammary solid carcinoma.</div><div><br /></div><div>KEYWORDS: Central nervous system, dog, mammary neoplasia.</div><div><br /></div> <div>Neoplasias mamárias são comuns entre as fêmeas caninas e os carcinomas, dentre as formas malignas, ocorrem com maior frequência, particularmente o tipo sólido. Estes podem apresentar-se pequenos e incipientes à macroscopia, contudo são invasivos e pouco diferenciados, com possibilidade de produzir metástases que comprometem a sobrevida do animal. Assim, descreve-se o caso de uma cadela, da raça Fila Brasileiro, de seis anos, que apresentou tetraplegia consequente à metástase medular cervical de carcinoma sólido mamário.</div><div><br /></div><div>PALAVRAS-CHAVES: Cão, neoplasia mamária, sistema nervoso central.</div><div><br /></div&gt

uPAR EXPRESSION IN CANINE NORMAL PROSTATE AND WITH PROLIFERATIVE DISORDERS

Prostatic lesions such as prostatic intraepithelial neoplasia (PIN) and proliferative inflammatory atrophy (PIA) are studied in human and canine species due to their malignance potential. The plasminogen activator (PA) system has been suggested to play a central role in cell adhesion, angiogenesis, inflammation, and tumor invasion. The urokinase-type plasminogen activator receptor (uPAR) is a component of the PA, with a range of expression in tumor and stromal cells. In this study, uPAR expression in both canine normal prostates and with proliferative disorders (benign prostatic hyperplasia-BPH, proliferative inflammatory atrophy-PIA, prostatic intraepithelial neoplasia-PIN, and carcinoma-PC) was evaluated by immunohistochemistry in a tissue microarray (TMA) slide to establish the role of this enzyme in extracellular matrix (ECM) remodeling and in the processes of tissue invasion. A total of 298 cores and 355 diagnoses were obtained, with 36 (10.1%) normal prostates, 46 (13.0%) with BPH, 128 (36.1%) with PIA, 74 (20.8%) with PIN and 71 (20.0%) with PC. There is variation in the expression of uPAR in canine prostate according to the lesion, with lower expression in normal tissue and with BPH, and higher expression in tissue with PIA, PIN and PC. The high expression of uPAR in inflammatory and neoplastic microenvironment indicates increased proteolytic activity in canine prostates with PIA, PIN, and PC

Matrix metalloproteinases 2 and 9 expression in canine normal prostate and with proliferative disorders

Este estudo teve como objetivo avaliar a expressão das metaloproteinases 2 (MMP-2) e 9 (MMP-9) em próstatas caninas normais e com desordens proliferativas, verificando o papel dessas enzimas na remodelação da matriz extracelular (MEC) e no processo de invasão tecidual. Um total de 355 amostras prostáticas foram obtidas, sendo 36 (10,1%) normais, 46 (13,0%) com hiperplasia prostática benigna (HPB), 128 (36,1%) com atrofia inflamatória proliferativa (PIA), 74 (20,8%) com neoplasia intraepitelial prostática (PIN) e 71 (20,0%) com carcinoma prostático (CP). Houve diferença de imunomarcação citoplasmática para MMP-2 e MMP-9 entre o epitélio acinar e o estroma periacinar, quanto aos diferentes diagnósticos. Observou-se correlação entre a expressão de MMP-2 e MMP-9 em relação ao número de células marcadas no epitélio acinar e estroma periacinar, bem como para a intensidade de marcação das células estromais periacinares em próstatas caninas com PIA. Conclui-se que há variação na expressão de MMP-2 e MMP-9 em próstatas caninas de acordo com a lesão, com menor expressão em próstatas caninas normais e com HPB, e maior naquelas com PIA, PIN e CP. Ainda, o microambiente inflamatório na PIA influencia a atividade de ambas as enzimas.In this study the expression of metalloproteinases 2 (MMP-2) and 9 (MMP-9) in canine normal prostates and with proliferative disorders was evaluated to verify the role of these enzymes in extracellular matrix remodeling (ECM) and in the tissue invasion process. A total of 355 prostatic samples were obtained, from which 36 (10.1%) were normal prostates, 46 (13.0%) with benign prostatic hyperplasia (BPH), 128 (36.1%) with proliferative inflammatory atrophy (PIA), 74 (20.8%) with prostatic intraepithelial neoplasia (PIN), and 71 (20.0%) with prostatic carcinoma (PC). Difference in cytoplasmic immunohistochemical staining of MMP-2 and MMP-9 between acinar epithelium and periacinar stroma was found regarding the different diagnosis. The correlation between MMP-2 and MMP-9 expression in relation to the number of labeled cells in acinar epithelium and periacinar stroma, as well as to the staining intensity in the periacinar stromal cells was evidenced in canine prostates with PIA. In conclusion, MMP-2 and MMP-9 expression has a variation in canine prostate according to the lesion, with lower expression in normal tissue and with BPH, and higher expression in those with PIA, PIN and PC. Moreover, the inflammatory microenvironment of the PIA has influence in the activity of both enzymes